JPS63218607A - Cosmetic compounded with extracted solution of thymus gland - Google Patents
Cosmetic compounded with extracted solution of thymus glandInfo
- Publication number
- JPS63218607A JPS63218607A JP62052744A JP5274487A JPS63218607A JP S63218607 A JPS63218607 A JP S63218607A JP 62052744 A JP62052744 A JP 62052744A JP 5274487 A JP5274487 A JP 5274487A JP S63218607 A JPS63218607 A JP S63218607A
- Authority
- JP
- Japan
- Prior art keywords
- solution
- thymus
- cosmetic
- extract
- thymus gland
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 32
- 210000001541 thymus gland Anatomy 0.000 title claims abstract description 31
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 20
- 241000283690 Bos taurus Species 0.000 claims abstract description 9
- 239000007858 starting material Substances 0.000 claims description 7
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 238000000605 extraction Methods 0.000 abstract description 31
- 230000007062 hydrolysis Effects 0.000 abstract description 12
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 12
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 6
- 238000001035 drying Methods 0.000 abstract description 4
- 239000000049 pigment Substances 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 48
- 239000000284 extract Substances 0.000 description 46
- 230000000694 effects Effects 0.000 description 34
- 102000003425 Tyrosinase Human genes 0.000 description 12
- 108060008724 Tyrosinase Proteins 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229940034252 thymus extracts Drugs 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Abstract
Description
【発明の詳細な説明】
〔イ〕 発明の目的
本発明は、改良きれた胸腺抽出溶液の化粧料への応用に
関するものである。DETAILED DESCRIPTION OF THE INVENTION [A] Object of the Invention The present invention relates to the application of an improved thymus extract solution to cosmetics.
本発明に用いる胸腺抽出溶液は、牛の胸腺かも、加水分
解して得られ、その特徴は、定量するとき、その溶液中
には、総窒素量が0.07w/V%以上含有することを
特徴とする。The thymus extract solution used in the present invention is obtained by hydrolyzing bovine thymus gland, and its characteristic is that when quantitatively determined, the solution contains a total nitrogen content of 0.07 w/v% or more. Features.
「従来の技術J
牛や豚等の動物(家畜類)の各種臓器から得られた抽出
物は、医薬をはじめ化粧料などに古(から応用きれてき
ている。``Conventional Technology J Extracts obtained from various organs of animals (livestock) such as cows and pigs have been used in pharmaceuticals and cosmetics since ancient times.
その中か−ら、動物の胸腺抽出溶液(エキス)を得る方
法として、次に示す方法が知られている。Among them, the following method is known as a method for obtaining an animal thymus extract.
(1)牛の胸腺を水性溶媒で抽出して得た、主として蛋
白質からなる抽出物を有効成分とする抗腫瘍剤(特公昭
61−8807)がある。(1) There is an antitumor agent (Japanese Patent Publication No. 61-8807) whose active ingredient is an extract mainly consisting of protein obtained by extracting bovine thymus with an aqueous solvent.
この他、一般的には、動物の臓器から、医薬や化粧料に
用いる抽出物には、有機溶媒を用いて得られた抽出溶液
、又は酸やアルカリ、又は螢自分解酵素を用いた加水分
解により得られた抽出溶液などがある。In addition, extracts from animal organs used for pharmaceuticals and cosmetics are generally extracted using an extraction solution obtained using an organic solvent, or hydrolyzed using an acid, alkali, or a firefly enzyme. There are extraction solutions obtained by
1発明が解決しようとする問題点」
牛の胸腺から抽出物を得て、これを化粧料に応用するこ
とが、最近、ヨーロッパにおいて注目されており、公知
である。しかし、その抽出法は詳しく開示きれていない
。1. Problems to be Solved by the Invention Recently, obtaining an extract from bovine thymus and applying it to cosmetics has attracted attention in Europe and is well known. However, the extraction method has not been disclosed in detail.
そこで本発明者らは、他の臓器からの、一般的な従来の
抽出法をもとに、化粧料への応用を試みることとし、次
表(第1表)に示す方法により、それぞれの抽出物を得
て、まず、作用(効果)との関係を確認することから研
究を開始した。Therefore, the present inventors decided to try applying to cosmetics based on general conventional extraction methods from other organs, and by the method shown in the following table (Table 1), each extraction After obtaining the product, we began our research by confirming the relationship with its action (effect).
その結果、第1表に示すごとくの手段をもとに抽出物を
得た。そして、第2表に示すごとくの成績結果を得るこ
とが出来た。As a result, extracts were obtained based on the methods shown in Table 1. As a result, we were able to obtain the results shown in Table 2.
つまり、公知な抽出法をもとに得られたもの:第1表中
の検体嵐1(有機溶媒処理によって得られたもの)、検
体N112(熱水抽出処理によって得られたもの)、検
体隘3(加水分解処理によって得られたもの)の三種類
の抽出物(エキス)を用いて、作用の確認のために、A
:組織切片に対する呼吸能(酸素の消費量)、B:チロ
シナーゼ活性抑制作用について試験を実施した。その結
果は、それぞれに異なった結果が得られたのである。In other words, those obtained using known extraction methods: Sample Arashi 1 (obtained by organic solvent treatment), Sample N112 (obtained by hot water extraction treatment), and Sample No. 1 in Table 1. In order to confirm the effect, three types of extracts (obtained by hydrolysis treatment) of A.
: Respiratory ability (oxygen consumption) on tissue sections; B: Tests were conducted on tyrosinase activity inhibitory effect. The results were different for each.
すなわち、チロシナーゼ活性抑制作用については、加水
分解による抽出物に強く示され、他の抽出法によるもの
に比べて効果が上回ることが確認出来た。In other words, it was confirmed that the tyrosinase activity inhibiting effect was strongly exhibited by the extract obtained by hydrolysis, and the effect was superior to that obtained by other extraction methods.
しかし、これと共に熱安定性をみると、いずれも不安定
であった。However, when looking at the thermal stability, all of them were unstable.
1第1表、 胸腺抽出物(エキス)の抽出法「第2表、
胸腺抽出物による作用の評価′第2表中の試験法A−
Bの注解」
[試験法A:組織呼吸能増加作用]
家兎皮膚組織切片に検体を添加し、ワールブルグ検圧計
を用いて、酸素消費量を求める方法で、対照には生理食
塩水を用いて実施、尚、末法についての評価値は、生理
食塩水以上に#素消費量の増加傾向を示したものについ
て、第2表中において、すべて(+)で示した。1 Table 1, Extraction method of thymus extract (Table 2)
Evaluation of the effects of thymus extract'Test method A- in Table 2
Comments on B" [Test method A: Effect of increasing tissue respiration capacity] A test sample was added to a rabbit skin tissue section, and oxygen consumption was determined using a Warburg manometer. Physiological saline was used as a control. In Table 2, all evaluation values for the final method are shown as (+) for those that showed a tendency to increase the # element consumption more than physiological saline.
[試験法B:チロジナーゼ活活性抑制作用及反応系デロ
ジン液(L−チロシン0,3■/鶴)3 mm、バy
77−液(01Mクエン酸と0.2Mリン酸水素2ナト
リウムでp)(5,g)3111、及び検体2.7 m
lをとり、37℃恒温水槽中に入れ、約10分間はど放
置後、チロシナーゼを溶解した液Q 、 3 mQを加
え、15分間経過後の溶液の475nmの吸光度を測定
、対照には精製水を用いて測定。[Test method B: Tyrosinase activity inhibitory effect and reaction system Derosin solution (L-tyrosine 0.3 / Tsuru) 3 mm, by
77-solution (p with 01M citric acid and 0.2M disodium hydrogen phosphate) (5, g) 3111, and specimen 2.7 m
1 was placed in a constant temperature water bath at 37°C, and left to stand for about 10 minutes. Then, 3 mQ of solution Q, in which tyrosinase was dissolved, was added, and the absorbance of the solution at 475 nm was measured after 15 minutes. Purified water was used as a control. Measured using.
尚、各試験法A−BJこ採用した検体は、共に、第1表
に示す抽出法(公知)をもとに得られた、抽出物の凍結
乾燥粉末を、3%含有する水溶液を用いた。但し、試験
法Aでは、さらに希釈し、02%含有する水溶液を調製
して、これを用いた。The specimens used in each test method A-BJ were an aqueous solution containing 3% freeze-dried powder of the extract obtained based on the extraction method (known) shown in Table 1. . However, in Test Method A, it was further diluted to prepare an aqueous solution containing 0.02%, and this was used.
次に、第2表に示す作用追試の結果をもとに、考察を加
えてみると、まず、3種類の胸腺抽出物について、その
共通した作用(効果)としては、他の臓器抽出物(例え
ば、肝臓や胎盤から抽出された抽出物)と同様にして、
組織呼吸能の増加作用が認められることであった。した
がって、このような呼吸能増加作用をもった抽出物は、
いわゆる肌の栄養源(剤)として、老化防止に役立つも
のとなり、肌に艶と張りを与え、抗しわ剤として効果的
なものであると考えられる。さらに、組織呼吸能を有す
るような抽出物の多くは、創傷等に対しては、炎症の緩
和又は緩衝剤としての役割を有し、局所組織の再生修復
剤として利用出来る。Next, based on the results of the effect test shown in Table 2, we consider the following: First, we find that the common effects (effects) of the three types of thymus extracts are similar to those of other organ extracts ( For example, extracts from the liver and placenta).
An effect of increasing tissue respiration capacity was observed. Therefore, extracts that have the effect of increasing respiratory capacity,
As a so-called skin nutrition source (agent), it is useful for preventing aging, gives luster and firmness to the skin, and is considered to be effective as an anti-wrinkle agent. Furthermore, many of the extracts that have tissue respiration ability have the role of alleviating inflammation or acting as a buffer for wounds, etc., and can be used as local tissue regeneration and repair agents.
しかし、第2表に示す成績結果をもとに化粧料への胸腺
抽出物の応用に関しては、さらに、改良を加える必要が
あることがわかった。However, based on the results shown in Table 2, it was found that further improvements were needed in the application of thymus extracts to cosmetics.
すなわち、作用(効果)について、チロジナーゼ活性の
抑制作用についてみると、3種類の抽出法の内、加水分
解抽出物が優れていることが確認されたことである。し
たがって、本発明者らは、この公知な抽出法をたたき台
として、安定性の良い、さらに優れた作用をもった胸腺
抽出物を得て、これを化粧料に応用することを目的とし
、その研究開発に当った。That is, in terms of action (effect), it was confirmed that the hydrolyzed extract is superior among the three extraction methods in terms of the inhibitory action on tyrosinase activity. Therefore, using this known extraction method as a base, the present inventors aimed to obtain a thymus gland extract with good stability and even superior action, and to apply this to cosmetics, and conducted research. I was in charge of development.
〔口〕 発明の構成
本発明による化粧料は、牛の胸腺を出発原料となし、加
水分解して得られた抽出溶液(エキス)の総窒素量が0
.07w/v%以上含有する抽出物を用いることにある
。[Mouth] Structure of the Invention The cosmetic according to the present invention uses bovine thymus as a starting material, and the total nitrogen content of the extracted solution (extract) obtained by hydrolysis is 0.
.. The purpose is to use an extract containing 0.07 w/v% or more.
1問題点を解決するための手段。A means to solve one problem.
胸腺抽出物を化粧料に応用するに当り、加水分解して得
られた抽出溶液の総窒素量が0.07 w/V%以上含
有するような溶液を化粧料に用いた例は、他に見当らな
い。When applying thymus extract to cosmetics, there are no other examples of using a solution in which the total nitrogen content of the extracted solution obtained by hydrolysis is 0.07 w/V% or more. I can't find it.
本発明者らは、第2表の成績結憂をもとに、化粧料に配
合して安定性の良好な、そして効果的(作用)な胸腺抽
出溶液を得るために、種々の改良を加えながら、得られ
た試作抽出物について、その作用を対比しながら研究に
当った。Based on the results shown in Table 2, the present inventors made various improvements in order to obtain a stable and effective thymus extract solution that can be incorporated into cosmetics. However, we conducted research while comparing the effects of the obtained trial extract.
その結果、次の実施例に示す方法による抽出溶液を用い
ることによって、安定性も良好であり、強いチロシナー
ゼ活性抑制作用を得ることに成功したのである。As a result, by using an extraction solution prepared by the method shown in the following example, we succeeded in achieving good stability and a strong tyrosinase activity inhibitory effect.
「実施例−1:抽出法コ
新鮮な牛の、凍結保存された胸腺を、ミンチカッターで
細砕し、有機溶媒を加え、攪拌を行い、脱水、脱脂した
後、乾燥して、出発原料となす0次に、出発原料に対し
て、水を約2倍量加えて攪拌した後、適当な酸を加えて
、pH3,0以下に調整後、さらに、65〜75℃で2
〜3時間加熱処理を行った後、アルカリでpH6〜7に
調整する。Example 1: Extraction method The frozen preserved thymus of a fresh cow is crushed with a mince cutter, an organic solvent is added thereto, stirred, dehydrated, defatted, dried, and used as the starting material. Next, about twice the amount of water was added to the starting material and stirred, and then an appropriate acid was added to adjust the pH to 3.0 or less, and the mixture was further heated at 65 to 75°C for 20 minutes.
After heat treatment for ~3 hours, the pH is adjusted to 6-7 with an alkali.
次に、蛋白分解酵素を加えて、加水分解を行う(この際
の反応条件としては、用いる蛋白分解酵素によって違い
があるが、ここでは、プロテアーゼ:科研製を用いて行
った)。Next, a protease is added to perform hydrolysis (the reaction conditions at this time vary depending on the protease used, but here, protease manufactured by Kaken was used).
反応終了後、用いた酵素を加熱下で失活させ、次に、こ
こで得られた分解液を濾過して得る。得られた分解液に
、精製水、エタノール、プロピレングリコール、1.3
−ブチレンゲリコール、クリセリンの内、1種又は2種
以上の混合液を加え、溶液中の総窒素量が、0.07w
/v%以上となるように調製を行い、防腐剤を添加後、
再度、0.2μmメンブランフィルタ−を用いて、再m
Aを行い、坂!1処理した後、胸腺抽出溶液を得る。こ
れを化粧料に用いる。After the reaction is completed, the enzyme used is inactivated by heating, and the resulting decomposition liquid is then filtered. Purified water, ethanol, propylene glycol, 1.3
- Add a mixture of one or more of butylene gellicol and chrycerin, and the total nitrogen amount in the solution is 0.07w.
/v% or more, and after adding preservatives,
Again, using a 0.2 μm membrane filter,
Do A and hit the slope! After one treatment, a thymus extract solution is obtained. This is used in cosmetics.
1実施例−2=抽出法。Example 1-2 = Extraction method.
新鮮な子牛の凍結保存された胸腺10kgを、ミンチカ
ッターで細砕し、n−ヘキサン10〜202を加え攪拌
を行い、脂質をn−ヘキサン層部に移行させ、胸腺破砕
物を分取、乾燥して、出発原料とする。10 kg of cryopreserved thymus of a fresh calf was crushed with a mincing cutter, 10 to 202 n-hexane was added and stirred to transfer the lipids to the n-hexane layer, and the crushed thymus was collected. Dry and use as starting material.
次に、出発原料に対して、水を約2倍量の割合で加え、
攪拌した後、少量の希硫酸を加えて、pH3,0以下に
調製後、さらに65〜75℃で2〜3時間加熱処理を行
った後、日周・水酸化ナトリウム試液で、pH6〜7に
調製する。Next, water is added at a ratio of about twice the amount of the starting material,
After stirring, add a small amount of diluted sulfuric acid to adjust the pH to below 3.0, further heat-treat at 65-75°C for 2-3 hours, and then adjust the pH to 6-7 using diurnal sodium hydroxide test solution. Prepare.
次に、蛋白分解酵素(プロナーゼ)を加え、加水分解を
行う(反応条件としては、40〜60°C14〜8時間
を熱処理を行い、反応終了後、加熱により用いた酵素を
失活させる)。Next, a proteolytic enzyme (pronase) is added to perform hydrolysis (reaction conditions include heat treatment at 40 to 60°C for 14 to 8 hours, and after completion of the reaction, the enzyme used is inactivated by heating).
加水分解後、濾過を行い、濾液を分取し、ここで得られ
た濾液を、減圧下で濃縮し、凍結乾燥して粉体状となし
、精製水の単独、又は精製水に、グリセリン又はプロピ
レングリ・コール、1.3−ブチレンゲリコールとの混
液中に溶解させ、その際には、溶液中の総窒素量が、0
.07w/v%以上となるように調製を行い、防腐剤を
添加後、再度、0.2μmメンブランフィルタ−を用い
て、再濾過を行い、滅菌処理した後、胸腺抽出溶液を得
る。これを化粧料に用いる。After hydrolysis, filtration is performed, the filtrate is separated, the filtrate obtained here is concentrated under reduced pressure, and lyophilized to form a powder. Purified water alone or purified water is mixed with glycerin or It is dissolved in a mixed solution of propylene glycol and 1,3-butylene glycol, at which time the total amount of nitrogen in the solution is 0.
.. After adding a preservative and filtering again using a 0.2 μm membrane filter and sterilizing, a thymus extract solution is obtained. This is used in cosmetics.
「実施例−3=抽出法。“Example-3 = Extraction method.
新鮮な子牛の胸腺を水洗後、ミンチカッターで細砕し、
脱水、脱脂した後、乾燥して原料とする。After washing fresh calf thymus, mince it with a mince cutter.
After dehydration and defatting, it is dried and used as raw material.
原料10−に対して、水201を加えて攪拌した後、希
硫酸を少量加えて、pH3,0以下にし、約70℃で2
〜3時間加熱処理し、日周―水酸化ナトリウム試液で、
pH6〜7にvI4tする。After adding water 201 to raw material 10- and stirring, a small amount of dilute sulfuric acid was added to make the pH 3.0 or less, and the mixture was heated at about 70°C.
After heat treatment for ~3 hours, diurnal cycle - sodium hydroxide test solution,
vI4t to pH 6-7.
次に、蛋白分解酵素(プロナーゼ)を加え、加水分解を
行う(反応条件として、40〜60℃、4〜8時間を加
熱処理を行い、反応終了後、用いた酵素を加熱下で失活
させる)。Next, a protease (pronase) is added to perform hydrolysis (reaction conditions include heat treatment at 40 to 60°C for 4 to 8 hours, and after the reaction is complete, the enzyme used is inactivated by heating. ).
加水分解後、濾過を行い、濾液を分取し、粧原基・プロ
ピレングリコール2.5kgを加えて、攪拌しながら混
和する。その際には、溶液中の総窒素量が、0.08〜
0.25w/v%となるように調製を行い、次に、11
7JjIl!剤として、粧原基−ソルピン酸カリウム0
.1%、粧原基・パラオキシ安息香酸メチル0.17%
、粧原基・パラオキシ安息香酸プロピル0.015%、
粧原基・パラオキシ安息香酸ブチル0.015%を添加
、溶解後、0.2μmメンブランフィルタ−を用いて再
濾過を行い、滅菌処理した後、胸腺抽出物溶液を得る。After hydrolysis, filtration is performed, the filtrate is separated, 2.5 kg of cosmetic primordium/propylene glycol is added, and the mixture is mixed with stirring. At that time, the total amount of nitrogen in the solution is 0.08~
Prepared to have a concentration of 0.25 w/v%, then 11
7JjIl! As an agent, makeup primordium-potassium sorbate 0
.. 1%, cosmetic primordium/methyl paraoxybenzoate 0.17%
, cosmetic primordium/propyl paraoxybenzoate 0.015%,
After adding and dissolving 0.015% of butyl paraoxybenzoate, the mixture is refiltered using a 0.2 μm membrane filter and sterilized to obtain a thymus extract solution.
これを化粧料に用いる。This is used in cosmetics.
「実施例−3」で特定した堕腐剤の組合せは、刺激を与
えず、溶液の安定性を向上し、しかも、乙の組合せは、
それを用いた化粧料の安定性にも好影響を与える。The combination of preservatives specified in "Example-3" does not cause irritation and improves the stability of the solution.
It also has a positive effect on the stability of cosmetics using it.
尚、実施例で得られた抽出溶液中には、水溶性の低分子
化されたペプチド類が移行しており、さらに、RNA+
DNA、ATPなども、かなり移行している。又、その
分子量分布状態をみると、加水分解における温度や時間
との関係で異なるも、例えば、実施例3によれば、分子
量100〜300付近のピーク、500付近を中心にし
たピーク、さらに、ピークが1千〜5千付近にあるもの
が得られる。In addition, water-soluble low-molecular-weight peptides have migrated into the extraction solution obtained in the example, and RNA +
DNA, ATP, etc. have also migrated considerably. Moreover, when looking at the molecular weight distribution state, although it differs depending on the temperature and time during hydrolysis, for example, according to Example 3, there is a peak around the molecular weight of 100 to 300, a peak centered around around 500, and A product with a peak around 1,000 to 5,000 is obtained.
1作用(効!J、)の確認」
実施例に示す抽出溶液をもとに、混合割合(濃度)を変
化きせた溶液を用い、第2表と同様の作用(効果)につ
いての評価を試みた。1. Confirmation of the effect (effect! Ta.
その結果は、第3表に示すごとくとなり、約0.07w
/v%以上の混合割合(i11度)では、作用が確実に
認められることがわかった。The results are shown in Table 3, approximately 0.07w
It was found that the effect was reliably observed at a mixing ratio of /v% or higher (i11 degrees).
「第3表ヨ 胸腺抽出溶液の作用に関する評価前装(第
3表)の成績結果から、実施例で得られた抽出溶液含有
水溶液は、少量でチロシナーゼ活性抑制作用が良好に示
されることである。From the results of the evaluation test (Table 3) regarding the effect of thymus extract solution, the extract solution-containing aqueous solution obtained in the example shows a good tyrosinase activity inhibiting effect in a small amount. .
すなわち、本発明による抽出溶液が示す、最適な効果(
作用)について、含有する成分組成の主な定量値から、
総窒素量を求めてみると、0.07w/v%以上であり
、呼吸能及びチロシナーゼ活性抑制作用が、共に良好で
あり、熱安定性(色調変化)も少なくなることがわかっ
た。すなわち、化粧料配合用として優れた溶液であるこ
とがわかった。That is, the optimal effect (
Regarding the effect), from the main quantitative values of the contained component composition,
When the total nitrogen amount was determined, it was found to be 0.07 w/v% or more, indicating that both respiratory ability and tyrosinase activity inhibitory effect were good, and thermal stability (color change) was also reduced. In other words, it was found that the solution was excellent for use in cosmetic formulations.
さらに、実施例で得られた抽出溶液について、紫外線吸
収スペクトルを求めてみると、第1図に示すごとくとな
り、約240〜28Onm付近にピークを有することが
確認きれた。Furthermore, when the ultraviolet absorption spectrum of the extracted solution obtained in the example was determined, it was as shown in FIG. 1, and it was confirmed that the ultraviolet absorption spectrum had a peak around about 240 to 28 Onm.
一方、実施例で得られた抽出溶液の成分からは、第4表
に示すごとく、総窒素量をもとに特定することによって
、従来の動物由来の抽出溶液に勝る、抽出溶液となすこ
とが可能である。On the other hand, from the components of the extraction solutions obtained in the examples, as shown in Table 4, by specifying them based on the total nitrogen content, it is possible to create an extraction solution that is superior to conventional animal-derived extraction solutions. It is possible.
次に、実施例で得られた抽出溶液の保湿作用についてみ
ると、第2図に示すごとくである。Next, looking at the moisturizing effect of the extract solution obtained in the example, it is as shown in FIG.
尚、試験法は、恒温恒湿機(高杉制作所製)により、気
温30℃における相対湿度20%、40%、60%及び
80%に、16時間静置したところの水分損失率を求め
たものである。In addition, the test method was to determine the moisture loss rate when the samples were allowed to stand for 16 hours at relative humidity of 20%, 40%, 60%, and 80% at a temperature of 30°C using a constant temperature and humidity machine (manufactured by Takasugi Seisakusho). It is something.
尚、実施例による抽出法をもとにすると、出発原料の胸
腺(未処理、乾燥前のもの)1kgから、最終的に得ら
れる収量は、その抽出物の凍結乾燥粉末に換算するとき
、最低で約60g、最高180gが得られた。Based on the extraction method described in the example, the final yield obtained from 1 kg of the starting material thymus (unprocessed, before drying) is the minimum yield when converted to the freeze-dried powder of the extract. Approximately 60g was obtained, with a maximum of 180g.
一方、次の第4表は、実施例により得られた抽出溶液に
ついて、その物性を示したものであるが、抽出溶液の長
期間の安定性の保持は、グリセリン、プロピレングリコ
ール、1.3−’チレングリコールを添加することによ
り、向上する。とくに、抽出溶液中に、総窒素量として
0.04%以上を含有するような場合では、これらのポ
リオール系溶媒の添加により、透明(清澄)な液性が維
持される。したがって、化粧水などでは、これらのポリ
オール系溶媒との併用が望ましい。On the other hand, Table 4 below shows the physical properties of the extraction solutions obtained in the examples. 'Improved by adding tylene glycol. Particularly, when the extraction solution contains 0.04% or more as a total nitrogen content, transparent liquid properties are maintained by adding these polyol solvents. Therefore, in lotions and the like, it is desirable to use these polyol solvents together.
「第4表、 胸腺抽出溶液の規格又は物性値次に、抽出
溶液のそれぞれの安定性について、低温〜40°C中で
、1ケ月間の経時的変化についてみると、第5表に示す
ごとくである。"Table 4. Standards or physical properties of thymus extract solution Next, regarding the stability of each extraction solution, we look at changes over time at low temperatures to 40°C for one month, as shown in Table 5. It is.
すなわち、本発明による抽出溶液は、熱安定性に優れて
いることである。その原因としては、抽出工程中の処理
が重要に係わっているものと考えられ、末法では、抽出
溶液を得る前処理として、脱脂、脱血と共に、一度乾燥
を行い、さらに酵素ニブaナーゼを用いて加水分解する
際に、希硫酸を用いた熱処理を行っていること、この操
作が、熱安定性に大きく寄与していることである。That is, the extraction solution according to the present invention has excellent thermal stability. The reason for this is thought to be that the treatment during the extraction process is important.In the final method, as a pretreatment to obtain the extraction solution, drying is performed along with defatting and blood removal, and then the enzyme nib-a-nase is used. During hydrolysis, heat treatment using dilute sulfuric acid is performed, and this operation greatly contributes to thermal stability.
1第5表ノ 熱安定性の評価
1処方例−1:化粧水」
実施例1〜3で得られた抽出溶液(但し、総窒素量とし
て0.5w/v%を含有するように調製した溶液)・・
・・・・・10〜30%ンコニツクスリキッドAB(シ
コン抽出色素含有溶液)・・・・・・・・・0.3〜0
,5%1.3−ブデレングリフール ・・・・2〜6%
香料及び防腐剤・・・・・・・・・・ 適 置端製水を
もって100となす。1 Table 5 Evaluation of thermal stability 1 Formulation example-1: Lotion Extract solutions obtained in Examples 1 to 3 (however, the extract solution was prepared to contain 0.5 w/v% as a total nitrogen amount) solution)··
...10 to 30% Nuconic liquid AB (solution containing pigment extracted from Niconia) ...0.3 to 0
, 5% 1.3-budelene glycol 2-6%
Fragrances and preservatives... Appropriate Make up to 100 with water at the end.
1処方例−2:乳液。1 Prescription example-2: Emulsion.
実施例1〜3で得られた抽出溶液(但し、総窒素量につ
いては、0.5w/v%に調製した溶液)・・・・・・
・・・t・・3〜20%ステアリン酸・・・・・・・・
・・・ 2.5%セチルアルフール・・−−■−−−1
,5%白色ワセリン・・・・・・・・・・・ 5.0%
流動パラフィン・・・・・・・・・ 10.0%ツイン
80・・・・・・・・1・・ 2.0%ポリエチレング
リフール(1500)・ 3.0%トリエタノールアミ
ン・・・・・・・ 1.0%香料及び防帽1・・・・・
・・・・ 適 置端製水をもってiooとなす。Extraction solutions obtained in Examples 1 to 3 (however, the total nitrogen content was adjusted to 0.5 w/v%)...
...t...3-20% stearic acid...
... 2.5% cetyl alfur... --■ ---1
, 5% white petrolatum... 5.0%
Liquid paraffin 10.0% Twin 80 1 2.0% polyethylene glycol (1500) 3.0% triethanolamine ... 1.0% fragrance and helmet 1...
・・・・・・ Take the water at the end and make it ioo.
′処方例−3:クリーム」
実施例1〜3で得られた抽出溶液(但し、総窒素量とし
てQ、5w/v%を含有するように調製した溶液)・・
・・・・・・・3〜6%ポリオキシエチレンオレイルエ
ーテル・1,6%ラノリンアルコール・・・・T1−−
1.8%ラノリン・・・・・・・・・・・・・ 5.4
%セタノール・・・・・・・・・・・・ 2.0%ビオ
デルマSX−19(ンアバター)・ 9.0%流動パラ
フィン・・・・・・・・・・ 6.0%モノステアリン
酸グリセリン・・・−2,0%オリザオイル5−1(米
胚芽油)・・ 4.0%パルミチン酸イソプロピル・・
・・ 10.0%セレシンψ・・・―・昏Φ・φ・優・
2.0%ホウ砂・・・・・・争・・・◆・・・ 1.
0%香料及び防腐剤・・・・・・・・・・ 適 置端製
水をもってZooとなす。'Formulation Example-3: Cream' Extract solutions obtained in Examples 1 to 3 (solutions prepared to contain Q, 5 w/v% as total nitrogen content)...
...3-6% polyoxyethylene oleyl ether, 1.6% lanolin alcohol...T1--
1.8% lanolin 5.4
%Setanol・・・・・・・・・ 2.0% Bioderma SX-19 (Navatar)・9.0% Liquid paraffin・・・・・・・・・ 6.0% Monostearic acid Glycerin...-2.0% Oryza oil 5-1 (rice germ oil)...4.0% Isopropyl palmitate...
・・10.0% Ceresin ψ・・・KomaΦ・φ・Excellent・
2.0% borax... Conflict...◆... 1.
0% fragrance and preservatives... Suitable Add water to the end and make it into a zoo.
〔ハ〕 発明の効果
本発明は5胸腺を加水分解することにより、得られた抽
出溶液の総窒素量が、0.07w/v%以上を含有する
ことを特徴とする1本発明による抽出溶液は、水溶性の
低分子化されたペプチド、アミノ酸が多く含有きれ、さ
らに、RNAやDNA% ATPが含まれている0本発
明による抽出物は、保湿作用に優れたもので、これを化
粧料に配合すると、皮膚(肌)や毛髪の乾燥を防ぎ、し
っとりとした、すべすべした柔軟性のある肌や髪に仕上
げてくれる。[C] Effects of the Invention The present invention provides an extraction solution according to the present invention characterized in that the total nitrogen content of the obtained extraction solution by hydrolyzing the thymus gland is 0.07 w/v% or more. The extract according to the present invention contains a large amount of water-soluble low-molecular-weight peptides and amino acids, and also contains RNA and DNA% ATP. When combined with this product, it prevents the skin and hair from drying out, leaving them moist, smooth, and flexible.
さらに、第3表に示すごとく、チロシナーゼ活性抑制作
用があり、肌の有色メラニンの生成を抑えることが期待
される。Furthermore, as shown in Table 3, it has a tyrosinase activity inhibitory effect and is expected to suppress the production of colored melanin in the skin.
すなわち、本発明による抽出物の特徴は、デロブナーゼ
に対する活性抑制作用を中心に、最善の抽出物の濃度を
求め、抽出溶液中に総窒素量として0.07w/v%以
上を含有する溶液を用いることにある。したがって、濃
度は化粧品への配合量(濃度)とも一致するわけで、肌
の有色メ2二ンの生成を抑制することを目的となし、用
いるに当っては、少なくとも化粧料中にも、抽出物の添
加量の目安としては、抽出物由来の総窒素量を定量する
とき、0.07w/v%以上が含士れていることが望ま
しい。That is, the characteristics of the extract according to the present invention are that the optimum concentration of the extract is determined with a focus on the activity inhibition effect on delobnase, and a solution containing 0.07 w/v % or more as a total nitrogen content in the extraction solution is used. There is a particular thing. Therefore, the concentration is the same as the amount (concentration) of cosmetics, and the purpose is to suppress the production of colored pigments on the skin. As a guideline for the amount of nitrogen added, when quantifying the total amount of nitrogen derived from the extract, it is desirable that the content be 0.07 w/v% or more.
従来、化粧料に用いられる臓器由来の抽出物は多いが、
これまでの添加量とチロシナーゼ活性抑制能から、その
最適な量の関係を求めたところのものは少なく、とくに
胸腺由来の抽出物については、本発明者らが、初めて見
出した関係である。Traditionally, many organ-derived extracts have been used in cosmetics, but
Until now, there have been few cases in which the relationship between the optimal amount has been determined based on the amount added and the ability to suppress tyrosinase activity, and the present inventors have discovered this relationship for the first time, especially for thymus-derived extracts.
又、第1rg:Jに示すごとく、紫外線吸収能を有し、
したがって、皮膚(肌)を直射日光から保護するのに役
立ち、美容上、そのもたらす効果も、大きなものがある
と言える。In addition, as shown in 1st rg: J, it has ultraviolet absorption ability,
Therefore, it can be said that it helps protect the skin from direct sunlight and has great cosmetic effects.
つまり、本発明の抽出物を用いれば、紫外線を吸収して
、これによる日焼け(メラニン色素の生成)を紡ぐと共
に、同時に、直接的にチロシナーゼ活性を抑制する、両
面の作用(相乗的効果)を有していることである。In other words, if the extract of the present invention is used, it will absorb ultraviolet rays and produce tanning (melanin pigment production), while simultaneously directly suppressing tyrosinase activity (synergistic effect). It is something that we have.
一方、化粧料に用いるに当って、一般的には臓器由来の
抽出物は、熱安定性が悪いとする欠点があり、これに伴
って、前記したごとくの最善の濃度(0,07w/v%
以上)が、配合できない場合が多かったが、第5表に示
したごとく、安定であることは、製剤化上も望ましいも
のであること、尚、クリームや乳涜では、加熱処理が加
わることが多いが、go”c、2〜3時間においては、
何ら安定性には問題なく、さらに、加熱処理後の抽出物
について、チロシナーゼ活性抑制作用についての試験を
行っても、その作用は維持きれており、低下は認められ
なかった。On the other hand, when used in cosmetics, extracts derived from organs generally have the disadvantage of poor thermal stability, and along with this, the optimum concentration (0.07 w/v) as mentioned above is required. %
However, as shown in Table 5, stability is desirable from the formulation standpoint, and it should be noted that heat treatment is not required for creams and milk products. There are many, but in 2 to 3 hours,
There were no problems with stability, and even when the heat-treated extract was tested for its tyrosinase activity inhibitory effect, the effect was maintained and no decrease was observed.
このことは、化粧料への応用に当って、大きなメリット
であり、水溶性タイプの化粧品類から、乳化や分散タイ
プの化粧品類、あるいは、粉体や固形状の化粧品類まで
、幅広く用いることが出来ることを意味している。但し
、化粧品類への配合に当って、その際、処方中の防腐、
防パイ剤の選択は重要であり、例えば、実施例3中に示
した、それぞれの薬剤の組合せが良好である。This is a great advantage when applied to cosmetics, and can be used in a wide range of applications, from water-soluble cosmetics to emulsion and dispersion cosmetics, as well as powder and solid cosmetics. It means that it is possible. However, when compounding into cosmetics, preservatives,
The selection of the anti-inflammatory agent is important, and for example, the combination of each agent shown in Example 3 is good.
第1図は、本発明によって得られた胸腺抽出溶液5%含
有水溶液の、紫外部吸収スペクトルである。
第2図は、本発明によって得られた胸腺抽出溶液(総窒
素量として、0.5%含有)による、保湿作用について
の効果を示すグラフである。FIG. 1 is an ultraviolet absorption spectrum of an aqueous solution containing 5% thymus extract obtained according to the present invention. FIG. 2 is a graph showing the moisturizing effect of the thymus extract solution (containing 0.5% total nitrogen content) obtained according to the present invention.
Claims (1)
られた、抽出溶液の総窒素量が0.07w/v%以上を
含有する溶液を配合することを特徴とする化粧料。(1) A cosmetic comprising a solution obtained by hydrolyzing bovine thymus as a starting material and containing an extracted solution containing a total nitrogen content of 0.07 w/v% or more.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62052744A JPS63218607A (en) | 1987-03-06 | 1987-03-06 | Cosmetic compounded with extracted solution of thymus gland |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62052744A JPS63218607A (en) | 1987-03-06 | 1987-03-06 | Cosmetic compounded with extracted solution of thymus gland |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS63218607A true JPS63218607A (en) | 1988-09-12 |
Family
ID=12923430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62052744A Pending JPS63218607A (en) | 1987-03-06 | 1987-03-06 | Cosmetic compounded with extracted solution of thymus gland |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63218607A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55176984U (en) * | 1979-06-04 | 1980-12-18 |
-
1987
- 1987-03-06 JP JP62052744A patent/JPS63218607A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55176984U (en) * | 1979-06-04 | 1980-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100613554B1 (en) | Cosmetics | |
JP3532244B2 (en) | Mucopolysaccharide fragmentation inhibitor, active oxygen scavenger and cosmetic | |
KR101746843B1 (en) | Use of a polyphenol-rich plant extract as antioxidant in combination with a hydrating or humectant agent | |
JP5210513B2 (en) | Cosmetics and extracts contained therein | |
JP2002507575A (en) | Use of at least one protein extract of Moringa plant seeds and corresponding cosmetic and / or pharmaceutical compositions | |
JP2597084B2 (en) | Cosmetic composition | |
AU2004270008B2 (en) | Cosmetic composition comprising camel milk | |
US4857328A (en) | Skin therapeutic mixture containing aloe vera extract | |
JP2003012489A (en) | Hyaluronidase activity inhibitor and moisture-retaining cosmetic | |
CN103547254B (en) | Containing the wrinkle improvement compositions from the composition of Placenta Hominis | |
JP2000309521A (en) | Skin lotion | |
JP2001316221A (en) | Antiaging agent and cosmetic | |
JP3513872B2 (en) | External preparation for skin | |
JPS6219511A (en) | Cosmetic for preventing aging of skin | |
US6955913B2 (en) | Unhydrolyzed jojoba protein products having high simmondsin concentration and methods of producing the same | |
JP3118020B2 (en) | Cosmetics | |
US6716599B2 (en) | Method of hydrolyzing defatted jojoba meal with protease enzymes | |
JPH1029927A (en) | Antiaging agent | |
JP2971549B2 (en) | Cosmetics | |
JPH069422A (en) | Promoter for biosynthesis of hyaluronic acid | |
JP2011195539A (en) | Elastase activity inhibitor | |
JPH0959124A (en) | Production of ultraviolet-ray-cutting agent and cosmetic containing the same | |
JP3272743B2 (en) | Placenta or liver extract having stable SOD activity and external preparation composition containing the same | |
JPS63218607A (en) | Cosmetic compounded with extracted solution of thymus gland | |
JP3044690B2 (en) | Cosmetics |